Viridian Therapeutics Inc (NASDAQ:VRDN) shares, rose in value on Thursday, November 21, with the stock price down by -0.86% to the previous day’s close as strong demand from buyers drove the stock to $19.62.
Actively observing the price movement in the last trading, the stock closed the session at $19.79, falling within a range of $19.46 and $20.375. The value of beta (5-year monthly) was 1.114. Referring to stock’s 52-week performance, its high was $27.20, and the low was $11.40. On the whole, VRDN has fluctuated by -16.12% over the past month.
With the market capitalization of Viridian Therapeutics Inc currently standing at about $1.55 billion, investors are eagerly awaiting this quarter’s results, scheduled for in December.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 52.83k.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that VRDN’s technical picture suggests that short-term indicators denote the stock is a Hold on average. However, medium-term indicators have put the stock in the category of 50% Buy while long-term indicators on average have been pointing out that it is a 100% Buy.
The stock’s technical analysis shows that the price of VRDN currently trading nearly -12.37% and -13.82% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 34.74, while the 7-day volatility ratio is showing 5.76% which for the 30-day chart, stands at 5.53%. Furthermore, Viridian Therapeutics Inc (VRDN)’s beta value is 1.07, and its average true range (ATR) is 1.30.
A comparison of Viridian Therapeutics Inc (VRDN) with its peers suggests the former has fared considerably weaker in the market. VRDN showed an intraday change of -0.86% in last session, and over the past year, it grew by 24.97%%.
Data on historical trading for Viridian Therapeutics Inc (NASDAQ:VRDN) indicates that the trading volumes over the past 10 days have averaged 1.59 and over the past 3 months, they’ve averaged 1.50 million. According to company’s latest data on outstanding shares, there are 79.21 million shares outstanding.
Nearly 11.45% of Viridian Therapeutics Inc’s shares belong to company insiders and institutional investors own 98.95% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 10.02 million shares as on 2024-10-31, resulting in a short ratio of 12.51. According to the data, the short interest in Viridian Therapeutics Inc (VRDN) stood at 1498.00 of shares outstanding as of 2024-10-31; the number of short shares registered in 2024-09-30 reached 10.15 million. The stock has fallen by -9.92% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the VRDN stock heading into the next quarter.
